May 24, 2017
Recommended Topic Related To:

Etopophos

"The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy.

Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonose"...

A A A

Etopophos




PATIENT INFORMATION

Myelosuppression

  • Advise patients that periodic monitoring of their blood counts is required. Advise patients to contact their healthcare provider for new onset of bleeding, fever, or symptoms of infection [see WARNINGS AND PRECAUTIONS].

Embryo-Fetal Toxicity

  • Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
  • Advise females of reproductive potential to use effective contraception during and 6 months after treatment with ETOPOPHOS [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
  • Advise males with female sexual partners of reproductive potential to use condoms during treatment with ETOPOPHOS and for at least 4 months after the final dose [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].

Last reviewed on RxList: 4/28/2017
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.